Journal
LANCET CHILD & ADOLESCENT HEALTH
Volume 4, Issue 1, Pages 68-79Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S2352-4642(19)30337-2
Keywords
-
Categories
Funding
- Centre for Research Excellence in Tuberculosis - National Health and Medical Research Council of Australia
- UK Medical Research Council under the MRC/DFID Concordat agreement [MR/R007942/1]
- UK Department for International Development (DFID) under the MRC/DFID Concordat agreement [MR/R007942/1]
- Wellcome Trust [206316/Z/17/Z]
- US National Institutes of Health [K01TW010829]
- MRC [MC_UP_ A900/1122, MR/K011944/1, MR/P024270/1]
- European Research Council under the European Union's Horizon 2020 research and innovation programme [757699]
- UK MRC [MR/P022081/1]
- MRC [MC_UU_00026/2, MR/R005990/2, MC_UP_A900_1122, MR/R007942/1, MC_PC_17221, MC_EX_MR/P024270/1, MR/P022081/1, MR/R005990/1, MC_EX_MR/K011944/1] Funding Source: UKRI
Ask authors/readers for more resources
Adolescence is characterised by a substantial increase in the incidence of tuberculosis, a known fact since the early 20th century. Most of the world's adolescents live in low-income and middle-income countries where tuberculosis remains common, and where they comprise a quarter of the population. Despite this, adolescents have not yet been addressed as a distinct population in tuberculosis policy or within tuberculosis treatment services, and emerging evidence suggests that current models of care do not meet their needs. This Review discusses up-to-date information about tuberculosis in adolescence, with a focus on the management of infection and disease, including HIV co-infection and rifampicin-resistant tuberculosis. We outline the progress in vaccine development and highlight important directions for future research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available